LifeVantage Corporation — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2014, and nine months ended March 31, 2014, compared with the same 2013 periods. This is fiscal 2014 third-quarter reporting; the request metadata’s “2013 Q3” does not match the filing period.
Business context and financial performance
LifeVantage sells nutraceutical supplements and skin-care products through independent distributors and preferred customers. Its principal product is Protandim; it also sells TrueScience skin care and Canine Health. The company operates in one segment and reports revenue across the Americas and Asia/Pacific.
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net sales | $55.1 million, up 9.3% from $50.4 million | $157.9 million, up 0.8% from $156.7 million |
| Gross margin | 84.6%, down from 86.4% | 84.7%, up from 81.3% |
| Operating income | $4.5 million, up from $3.9 million | $14.7 million, up from $11.8 million |
| Net income | $2.5 million, down from $3.4 million | $9.0 million, up from $7.8 million |
| Diluted earnings per share | $0.02, versus $0.03 | $0.08, versus $0.06 |
Quarterly sales growth was led by Asia/Pacific, up 29.8%, including Japan up 25.6% and Hong Kong up 89.4%; Americas revenue declined 1.4%. For the nine-month period, Americas revenue rose 3.9%, while Asia/Pacific revenue fell 4.4%, including Japan down 12.6%.
Cash flow, debt and liquidity
- Nine-month operating cash flow was $10.2 million, compared with $10.1 million in the prior-year period. Capital expenditures were $1.7 million, versus $4.6 million.
- Cash and cash equivalents were $35.7 million at March 31, 2014, up $9.4 million from June 30, 2013. Working capital was $31.0 million, compared with $25.4 million.
- Debt principal outstanding was $45.8 million, including a $4.7 million short-term portion. The company also had a $20 million delayed-draw facility, unused at quarter-end. The term loan bears interest at 8.75% for the reported nine-month period, is secured by substantially all company assets, and matures no later than October 2018.
- Cash used for the $40 million tender-offer share repurchase was substantially financed with the term loan. The company repurchased 16.3 million shares in the tender offer; it also completed a separate $5 million repurchase authorization. Stockholders’ equity fell to $2.7 million from $33.9 million at June 30, 2013, principally reflecting the repurchase and accumulated deficit.
- Management said cash and expected operating cash flow should meet requirements for at least the next 12 months. Contractual obligations disclosed total $76.9 million, including debt, estimated interest and operating leases.
Changes, outlook and risks
- Foreign currency movements reduced revenue by $2.3 million in the quarter and $9.8 million for the nine months; the weaker yen particularly affected reported Japan sales. A 20% Japan price increase took effect April 1, 2014.
- Quarterly gross margin declined amid higher shipping and warehousing costs for new international markets. Nine-month gross margin improved primarily because the prior-year period included $5.4 million of product-recall costs. The company expected a benefit from reworking recalled inventory within the next two quarters.
- Sales and marketing costs increased, mainly from distributor commissions, incentives, events and a jersey-front sponsorship. Management expected these costs to rise slightly in the remainder of fiscal 2014; R&D spending was expected to increase slightly, while operating expenses as a percentage of revenue were expected to remain relatively consistent.
- Active independent distributors increased 15.9% year over year to 73,000, while active preferred customers declined 4.3% to 134,000. The company identified distributor attraction and retention as key drivers of sales. It introduced a new full line of TrueScience skin-care products in April 2014.
- At March 31, foreign cash exceeded the credit agreement’s $5.5 million covenant limit, a non-financial covenant violation. The lender waived the violation on April 7, 2014. The company reported compliance with other applicable covenants and anticipated continued compliance, but covenant breaches could accelerate repayment and constrain financing, repurchases or other actions.
- Key risks include foreign-exchange exposure, debt service and restrictive covenants, reliance on distributors and key products, regulation of direct selling and supplements, product acceptance, and dependence on third-party manufacturers. The company reported no legal proceedings; management considered the likelihood of an adverse outcome in pending litigation remote.
Investor verification priorities
- Verify subsequent Japan sales and margins after the 20% price increase, including the effect of yen movements.
- Track distributor and preferred-customer trends, especially the decline in preferred customers, and the sales contribution of newly introduced products.
- Review operating cash generation against scheduled debt principal and interest payments, covenant thresholds, and the status of any future covenant waivers.
- Confirm the timing and amount of any benefit from recalled-inventory rework and related insurance recoveries.
- Assess the impact of the large tender-offer repurchase on leverage, liquidity and the sharply reduced stockholders’ equity.